Dicerna Announces Novo Nordisk’s Nomination of First Candidate for Development Under RNAi Discovery and Development Agreement and Additional Milestone Achievement
Dicerna Pharmaceuticals (Nasdaq: DRNA) announced that Novo Nordisk has nominated its first candidate for treatment of liver-related cardiometabolic diseases under their collaboration. This nomination is a significant milestone for Dicerna, demonstrating the effectiveness of their GalXC™ RNAi platform technology. Over the past year, the partnership has led to the identification and validation of multiple therapeutic candidates, showcasing the productive nature of their relationship.
- Novo Nordisk nominated its first candidate under the agreement with Dicerna.
- Collaboration has led to the identification and validation of multiple candidates.
- Demonstrates the effectiveness of Dicerna's GalXC™ RNAi platform technology.
- None.
Dicerna Pharmaceuticals, Inc. (Nasdaq: DRNA) (the “Company” or “Dicerna”), a leading developer of investigational ribonucleic acid interference (RNAi) therapeutics, today announced Novo Nordisk A/S (“Novo”) has nominated its first candidate under the existing agreement between the two companies for the discovery and development of novel therapies for the treatment of liver-related cardiometabolic diseases using Dicerna’s proprietary GalXC™ RNAi platform technology.
“The past 12 months since closing our agreement with Novo have been extremely productive, with the identification and validation of multiple candidates under this highly collaborative relationship,” said Bob D. Brown, Executive Vice President and Head of Research and Development at Dicerna. “Tha
FAQ
What is the latest news about Dicerna Pharmaceuticals (DRNA)?
How has the collaboration with Novo Nordisk benefited Dicerna Pharmaceuticals?
What technology does Dicerna use for its therapeutic development?
